Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMRX
stocks logo

AMRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
808.15M
+10.63%
0.180
+50.07%
741.79M
+6.67%
0.193
-7.94%
767.74M
+5.97%
0.217
-13.33%
Estimates Revision
The market is revising Upward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by 0.42% over the past three months. During the same period, the stock price has changed by 24.12%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.42%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.12%
In Past 3 Month
Stock Price
Go Up
up Image
+24.12%
In Past 3 Month
Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.940
sliders
Low
10.00
Averages
High
10.00
Current: 11.940
sliders
Low
10.00
Averages
High
10.00
Piper Sandler
Overweight
maintain
$11 -> $13
2025-10-31
Reason
Piper Sandler
Price Target
$11 -> $13
2025-10-31
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Amneal Pharmaceuticals to $13 from $11 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 17c on revenue of $784.5M, compared to Street estimates of 14c and $773.9M, respectively.
JPMorgan
Chris Schott
Overweight
maintain
$12 -> $14
2025-09-16
Reason
JPMorgan
Chris Schott
Price Target
$12 -> $14
2025-09-16
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Amneal Pharmaceuticals to $14 from $12 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but increased price targets on a move to December 2026 from December 2025.
Goldman Sachs
Matt Dellatorre
Buy
initiated
$12
2025-06-06
Reason
Goldman Sachs
Matt Dellatorre
Price Target
$12
2025-06-06
initiated
Buy
Reason
Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals with a Buy rating and $12 price target. The firm expects continued momentum across the portfolio and sees upside to consensus estimates. Goldman sees Amneal's generics segment remaining the key component and driver of EBITDA growth, driven by the company's strong product pipeline, including biosimilar and sterile injectable launches.
Barclays
Balaji Prasad
Buy
Maintains
$10 → $11
2025-03-03
Reason
Barclays
Balaji Prasad
Price Target
$10 → $11
2025-03-03
Maintains
Buy
Reason
JP Morgan
Chris Schott
Hold
to
Buy
Upgrades
$9 → $12
2025-02-24
Reason
JP Morgan
Chris Schott
Price Target
$9 → $12
2025-02-24
Upgrades
Hold
to
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX.N) is 14.10, compared to its 5-year average forward P/E of 7.89. For a more detailed relative valuation and DCF analysis to assess Amneal Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
7.89
Current PE
14.10
Overvalued PE
11.30
Undervalued PE
4.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.88
Undervalued EV/EBITDA
5.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.49
Current PS
0.00
Overvalued PS
0.80
Undervalued PS
0.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AMRX News & Events

Events Timeline

(ET)
2025-12-02
08:20:00
Amneal Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
select
2025-12-01 (ET)
2025-12-01
16:10:00
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%
select
2025-11-13 (ET)
2025-11-13
17:15:47
Amneal Pharmaceuticals Receives FDA Approval for Iohexol Injection
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
Amneal Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol with $1.5B Market Potential
  • Product Approval: Amneal's albuterol sulfate inhalation aerosol has received FDA approval, becoming the generic equivalent of Teva Respiratory's PROAIR®HFA, which is expected to significantly enhance the company's market share.
  • Market Opportunity: According to IQVIA, the annual sales for albuterol sulfate inhalation aerosol in the U.S. are approximately $1.5 billion, indicating the product's importance and potential revenue in the respiratory drug market.
  • Strategic Development: This approval complements the company's earlier FDA approval of beclomethasone dipropionate inhalation aerosol, marking Amneal's ongoing progress in the complex respiratory drug category and strengthening its competitive product portfolio.
  • Growth Potential: Amneal executives noted that these achievements stem from years of hard work and investment, which are expected to drive the company's long-term growth and patient impact in the respiratory drug sector.
[object Object]
Preview
9.0
12-02NASDAQ.COM
FDA Grants Approval for Amneal Pharma's Generic Version of RESTASIS for Treating Dry Eye Disease

  • FDA Approval: Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a generic version of AbbVie's RESTASIS, aimed at treating dry eye disease.

  • Product Details: The product is a sterile formulation in single-use vials designed to increase tear production in patients with dry eye syndrome due to ocular inflammation.

  • Market Impact: The U.S. annual sales for this medication were approximately $2.0 billion for the year ending September 2025, highlighting its significant market potential.

  • Launch Timeline: Amneal plans to launch the product in the first quarter of 2026, addressing a condition that affects an estimated 16.4 million adults in the U.S.

[object Object]
Preview
9.0
12-02NASDAQ.COM
Amneal Pharma Gets FDA Green Light for 0.05% Cyclosporine Ophthalmic Emulsion

  • FDA Approval: Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a generic version of Allergan's RESTASIS, designed to treat dry eye syndrome by increasing tear production.

  • Indications and Usage: The product is indicated for patients with suppressed tear production due to ocular inflammation, but it is not effective for those currently using topical anti-inflammatory drugs or punctal plugs.

  • Adverse Reactions: The most common side effect reported with the use of cyclosporine ophthalmic emulsion 0.05% is ocular burning.

  • Market Potential: The annual sales for this formulation in the U.S. were approximately $2.0 billion for the year ending September 2025, indicating significant market demand.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) stock price today?

The current price of AMRX is 11.94 USD — it has decreased -1.97 % in the last trading day.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s business?

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

arrow icon

What is the price predicton of AMRX Stock?

Wall Street analysts forecast AMRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is  USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s revenue for the last quarter?

Amneal Pharmaceuticals Inc revenue for the last quarter amounts to 784.51M USD, increased 11.68 % YoY.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s earnings per share (EPS) for the last quarter?

Amneal Pharmaceuticals Inc. EPS for the last quarter amounts to 0.01 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Amneal Pharmaceuticals Inc (AMRX)'s fundamentals?

The market is revising Upward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by 0.42% over the past three months. During the same period, the stock price has changed by 24.12%.
arrow icon

How many employees does Amneal Pharmaceuticals Inc (AMRX). have?

Amneal Pharmaceuticals Inc (AMRX) has 8100 emplpoyees as of December 05 2025.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) market cap?

Today AMRX has the market capitalization of 3.75B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free